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Background: Atrial fibrillation (AF) is a prevalent arrhythmia associated with symptoms such 
as irregular heartbeat, palpitations, dyspnea, chest pain and fatigue. In many patients, AF 
symptoms are not alleviated by current treatment strategies and there is a clinical need for better 
symptom management. AF is associated with low quality of life (QoL) and psychological 
distress, and patients often present with symptom preoccupation; i.e., fear of AF symptoms and 
avoidance behavior. Symptom preoccupation may play an important role in AF disability and 
is associated with higher self-reported symptom severity and low QoL.  
Aims: The overall objective of this doctoral project is to develop and evaluate a novel, AF-
specific, exposure-based internet-delivered cognitive behavior therapy (AF-CBT) protocol to 
increase QoL and potentially reduce symptom burden in patients with symptomatic paroxysmal 
AF. The specific aims consist of the following: 
o investigate the feasibility, acceptability and potential efficacy of a novel treatment 
protocol of exposure-based AF-CBT delivered face-to-face (Study I) or via the Internet 
(Study II); 
o investigate the efficacy of internet-delivered exposure-based AF-CBT compared to a 
waitlist receiving standardized AF education (Study III); 
o investigate if reduction in symptom preoccupation, i.e., cardiac-related fear, 
hypervigilance and avoidance behavior, mediates the therapeutic effect of AF-CBT 
(Study IV). 
Methods: The feasibility, acceptability and potential efficacy of the AF-CBT protocol were 
evaluated in two uncontrolled pilot studies (Study I and II). The treatment’s efficacy was further 
investigated in a randomized controlled trial (RCT), where a total of 127 participants were 
randomized to 10 weeks of AF-CBT (n=65) or to a waitlist offered standardized AF education 
(AF-EDU; n=62 (Study III)). All participants were diagnosed with paroxysmal symptomatic 
AF and were referred by a cardiologist (Study I and II) or self-referred (Study III). The 
participants underwent thorough cardiac evaluations and psychological assessments to ensure 
that they received medical treatment according to current guidelines. The treatment was 
therapist-guided exposure-based AF-CBT delivered face-to-face (Study I) or over the Internet 
(Study II and III) for 10 weeks. The treatment targeted two proposed maintaining factors of AF 
disability: fear of AF symptoms and AF-related avoidance behavior. The primary outcome was 
AF-specific QoL and secondary outcomes included, among others, self-reported AF 
symptoms, symptom preoccupation, general QoL, depression, stress, healthcare utilization and 
objective AF burden measured by electrocardiogram (ECG). In order to explore potential 
mediators of the treatment effect, data from the RCT was used to conduct a mediation analysis, 
with weekly assessments of three putative mediators (cardiac-related fear, hypervigilance and 




Results: AF-CBT rendered high adherence, satisfaction and treatment completion (Study I-
III). We observed large to medium effect sizes, with stable effects six-months after the 
treatment (Study I and II). In Study III, AF-CBT led to large and superior between-group 
improvement in AF-specific QoL (primary outcome) three months after the treatment. 
Significant improvements were also observed on all relevant outcomes in favor of AF-CBT. 
The results were sustained 12 months after the treatment. No significant difference in objective 
AF burden between the groups at three-month follow-up was detected. The analysis of 
mediators showed that a reduction in symptom preoccupation, i.e., cardiac-related fear, 
hypervigilance and avoidance behavior mediated the treatment effect of self-reported AF 
symptoms and disability.  
Conclusion: Internet-delivered exposure-based AF-CBT is feasible, acceptable and clinically 
effective for patients with AF. The results support a treatment strategy targeting symptom 
preoccupation via exposure-based CBT to reduce AF symptoms and disability. AF-CBT 
administered via the Internet has the capacity to ameliorate the well-being of a large group of 
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The rhythm of our hearts affects our mental and emotional experiences, and the 
communication between the heart and brain is an ongoing, dynamic dance, with each organ 
continuously influencing the other’s function (1). With atrial fibrillation (AF), the heartbeat is 
often chaotic and it is understandable that AF patients respond with negative emotions and 
behavioral adjustments to that chaos. This quite often leads to a vicious cycle of fear and 
avoidance, where AF dictates the rhythm of the patient’s life.  
AF is a prevalent arrhythmia and many patients experience disabling symptoms and impaired 
quality of life. There are few easily accessible and effective treatment options available to 
alleviate AF. There is a bidirectional relationship between mental health and cardiovascular 
diseases (2), and psychological factors are known to play a role in the clinical course in AF, 
although patients with AF are rarely assessed or considered for psychological treatment.   
My interest in exploring the interplay of psychological factors in somatic diseases emerged 
during my practice as a clinical psychologist, where I often treated psychological conditions 
comorbid with somatic disorders. Most commonly, the physical and mental aspects of patients’ 
health were treated as two separate units within the healthcare system. During the course of my 
doctoral education I have found it instructive and rewarding to work towards bridging this gap 
and expanding cognitive behavior therapy (CBT) for a new patient group.  
This thesis describes how I, together with my supervisors and colleagues, developed and 
evaluated a novel CBT treatment for AF and how we explored psychological factors in AF. 
The results are limited by design and methods, but hopefully this thesis will mark the start of 
a journey continuing to bring the heart and mind closer in clinical practice for the benefit of a 
large patient group.  
 








2.1 ATRIAL FIBRILLATION 
2.1.1 What is atrial fibrillation? 
Atrial fibrillation (AF) is caused by disturbances of electrical signaling in the two upper heart 
chambers (atria). During AF, electrical activity in the atria is chaotic, resulting in an irregular 
and often fast activation of the main chambers (ventricles) and dyssynchrony between atrial 
and ventricular mechanical function (3). Commonly, AF episodes are triggered by rapid 
electrical activity arising from the pulmonary veins inserting into the posterior wall of the left 
atrium. When patients have AF, not only do they experience a rapid and irregular heartbeat but 
also symptoms such as chest pain, dizziness, weakness and shortness of breath that may range 
from mild to disabling (4). Sometimes, however, AF may be asymptomatic. The following 




Figure 1. Illustration of the electrical signaling in AF.  
 
2.1.2 Prevalence 
AF is the most common arrhythmia with an estimated prevalence of 2-4 % in the general adult 
population, and the prevalence shows an upward trajectory in the population worldwide (5). 
Factors contributing to its increase include extended longevity, better detection of AF as well 
as increased incidence of other cardiovascular risk factors predisposing to AF (6). Advanced 
age is a major risk factor for AF, and the corresponding prevalence for patients older than 80 
years is approximately 10% (7). The prevalence of AF is lower in women, but the risk for 
complications, such as stroke, is similar or even higher compared with men with AF (6,8). 
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2.1.3 Diagnosis and classification of AF 
A rhythm documentation using an 12-lead electrocardiogram (ECG) or recording of a rhythm 
strip lasting for at least 30 seconds is required to diagnose AF (9).  AF is classified based on its 
pattern, duration and how or when it may or may not convert back to normal cardiac rhythm. 
The classification of paroxysmal AF implies that the AF episodes are intermittent, commonly 
start suddenly and last briefly or for days and then convert back to normal cardiac rhythm 
within seven days. The classification of persistent AF suggests that the arrhythmia does not 
self-terminate and requires medical procedures, such as cardioversion, to restore normal 
cardiac rhythm (10). Patients who have had continuous AF for more than one year receive a 
diagnosis of permanent AF (10). The natural course of AF is that it often progresses from 
paroxysmal to permanent, which means that the AF burden increases over time, with AF 
episodes becoming more frequent or of longer duration (11).  
AF episodes may be both symptomatic, where the patient can feel symptoms of AF, and 
asymptomatic, also referred to as “silent AF”. It is also common for patients to experience both 
symptomatic and asymptomatic AF episodes (12). Since AF can lead to stroke and other severe 
health consequences, an early diagnosis and screening of risk groups is important to identifying 
asymptomatic AF (13).  
2.1.4 Etiology 
Current evidence suggests that the etiology of AF is caused by multiple interacting factors, 
such as hereditary components, and clinical risk factors predisposing for AF, such as 
advanced age, diabetes mellitus, hypertension, valve disease, congestive heart failure, obesity 
and obstructive sleep apnea (14). A sedentary lifestyle has been associated with an increased 
risk for AF; interestingly, extreme levels of physical activity, for example endurance sports, 
confers an elevated AF risk as well (15). A common pathophysiological pathway of these 
conditions is that they are associated with enlargement or fibrotic remodeling of the atria, 
thus providing a biological and structural substrate facilitating the initiation and perpetuation 
of AF (3). Furthermore, there is also emerging evidence suggesting that psychological 
conditions, such as post-traumatic stress disorder, are associated with an elevated risk of 
developing AF (16).  
2.1.5 Mortality and morbidity 
Although the arrhythmia itself is not lethal, it is associated with a substantially increased risk 
for all-cause mortality (due to associated comorbidity, such as heart failure) (17) and morbidity 
such as acute coronary syndrome and stroke (18). AF is also associated with anxiety disorders 
and depression (19) as well as with high rates of healthcare utilization and hospitalization, 
leading to an increased economic burden on society (20). Healthcare utilization and cost has 
also been shown to vary according to the clinical course of AF, and has been shown to be 
markedly higher in paroxysmal AF patients compared with those with permanent AF (21).  
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2.1.6 Quality of Life 
AF significantly impairs quality of life (QoL) in a large proportion of patients. AF patients have 
both lower QoL compared with healthy controls (22) and are also comparably disabled or more 
disabled than patients with structural heart disorders, such as heart failure (23). Low QoL in 
AF is also associated with a higher risk for hospitalization (23). In a study using data from a 
large community-based AF registry, several patient factors were shown to be associated with 
low QoL including younger patients, women and patients with comorbid diseases, such as 
obstructive sleep apnea and hypertension. Patients with new onset of AF were shown to have 
lower QoL than those with permanent AF, whereas paroxysmal and persistent AF did not show 
to differ in QoL (24). 
2.2 PSYCHOLOGICAL FACTORS IN AF  
A factor that has been shown to impact QoL and AF disability is how patients interpret and 
perceive their AF symptoms (25). QoL in AF has also been shown to be impaired irrespective 
of arrhythmia burden (duration and frequency of symptoms) when measured objectively (26, 
27), suggesting that symptoms and their impact extend beyond the objective arrhythmia burden 
and anticipation of disruptive symptoms may have a depressant effect on QoL. AF can be 
divided in to either objective AF burden, measured by ECG monitoring, or subjective AF 
symptoms, measured by self-report. When investigating the relationship between objective AF 
episodes, recorded by ECG and patients’ subjective perceptions of AF symptoms, it has been 
shown that it is difficult for patients to correctly estimate their AF burden. Concurrent mood 
disorder and psychological distress have been linked to patients overestimating their actual AF 
burden (28). Furthermore, a study by McCabe et al. (29) showed that patients with recurrent 
AF, who perceived their symptoms as unpredictable and potentially leading to serious health 
consequences, reported increased psychological distress compared with patients with more 
understanding of the diagnosis and less perceived negative consequences. 
2.2.1 Anxiety, depression and perceived stress  
Psychological factors have a bidirectional relationship with AF, where symptoms may lead to 
a deterioration in mental health that, in turn, may have a negative effect on the short- and long-
term clinical course. Many studies have concluded that depression and anxiety are elevated in 
AF patients, with estimates ranging from 25 to 50% (30). In a study by Thrall et al. it was found 
that 38% of patients with AF had elevated levels of depression, measured by the Beck 
Depression Inventory, and the same number corresponded to elevated anxiety according to the 
State-Trait Anxiety Inventory (31). The levels of depression in AF were comparable to patients 
with other chronic diseases, while the levels of anxiety were found to be significantly higher in 
AF than in other patient groups living with chronic diseases.  
Anxiety and depression also lead to an increase in perceived intensity of AF symptoms and 
more healthcare seeking irrespective of objectively measured AF burden (28). Depression has 
been shown to be a significant predictor of AF recurrence following cardioversion (32) and has 
been associated with increased cardiovascular mortality in patients with AF (33). Furthermore, 
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enhanced stress has been found to trigger and increase the risk for recurrent symptomatic AF 
episodes (34). Stress is frequently reported as a trigger for AF by patients in clinical settings 
and research (35) and has also been associated with elevated levels of anxiety and depression 
(29).  
2.2.2 Symptom preoccupation: an AF-specific psychological approach  
In summary, anxiety and depression are common comorbid conditions in AF affecting QoL 
and potentially the clinical course of AF. However, previous research does not explain how 
AF-specific psychological factors may lead to development of AF-related disability. This 
doctoral project aims to explore a more disease-specific approach by defining AF-related 
psychological factors in terms of cardiac-related fear and avoidance behaviors. The 
discordance between objective AF episodes and perceived AF symptoms and the relationship 
between psychological factors and perceived symptom burden suggest that symptom 
preoccupation may play a role in the development of AF disability. Symptom preoccupation 
in AF has been shown to be associated with increased symptom burden, depression and anxiety, 
and poor QoL  (36). Interestingly, these findings are similar to those described in other somatic 
and functional disorders, such as chronic pain and irritable bowel syndrome (IBS), where 
symptom preoccupation has been shown to be associated with symptom severity, functional 
disability, healthcare seeking, depression and anxiety (37). We have further conceptualized 
symptom preoccupation in AF as A) fear of starting and experiencing AF episodes; B) 
hypervigilance to cardiac and AF-related symptoms; C) worry about cardiac health and 
potential complications (e.g., stroke); and D) AF-related avoidance behavior; e.g., avoidance 
of social or physical activities (38,39). Symptom preoccupation in AF, with the assumption 
that cardiac-related fear and avoidance behavior leads to a disproportionate AF disability, can 
be described as an analogue to the fear/avoidance model of chronic pain (40), where the 
individual’s interpretation of bodily pain leads to long-term maladaptive avoidance responses 
and impairments (41). Two of the main psychological components in symptom preoccupation 
are described below.  
2.2.2.1 Cardiac-related fear and hypervigilance  
As mentioned earlier, AF patients show a poor correlation between subjectively perceived AF 
symptoms and objectively measured AF episodes (26,27). Thus, AF patients frequently 
misinterpret cardiac activity related to stress or physical exertion as arrhythmia (i.e., 
hypervigilance). For patients with AF, both AF symptoms and normal cardiac activation may 
be conditioned with fear or negative emotional responses through respondent conditioning 
(42). This kind of interoceptive conditioning has been found to play a key role within panic 
disorders, but also in patients with, for example, non-cardiac chest pain (42) where bodily 
sensations, such as a slight change in heart rate or breathlessness, may trigger a fear response. 
In experimental research, interoceptive conditioning has been found to enhance the perception 
and reaction to bodily symptoms (43), meaning that the fear and hypervigilance towards 
cardiac-related symptoms may also make the patient more prone to react with anxiety. The 
anxiety leads to an increase in arousal in the autonomic nervous system and heart rate which, 
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in turn, can start extra beats and potentially AF episodes (44). Anxiety has been shown to be a 
predictor of AF, where multiple studies have indicated an association between elevated levels 
of anxiety and the recurrence of AF symptoms (45). Thus, the enhanced fear and 
hypervigilance of cardiac symptoms lead to increased subjective symptom burden and when 
patients react with fear they may even trigger AF symptoms.  
2.2.2.2 AF-related avoidance behavior  
In a qualitative study by McCabe et. al (46), symptom preoccupation in patients living with AF 
was highlighted. One prominent theme was their fruitless attempts to control the onset of AF 
by avoiding certain situations or activities. Patients described the inability to control symptom 
onset as distressing, leading to increased control behaviors by, for example, seeking the cause 
of recurrent AF episodes. Despite making adjustments in everyday life, the patients were often 
still not able to avoid recurrent episodes of AF, which caused distress and the perception of a 
personal failure (46). AF-related avoidance behavior serves to decrease anxiety and cardiac-
related symptoms and is developed and maintained through operant conditioning (42). 
Avoidance behavior in AF can include overtly avoiding physical activities or social situations 
where symptoms are unwanted or by monitoring one’s heartbeat or trying to distract oneself 
from the heart (47). When AF patients avoid social and physical activities while experiencing 
symptoms or in anticipation of symptoms, they also maintain their fearful responses to AF 
symptoms, as commonly seen in anxiety disorders (48). AF patients also become more 
impaired in the long run as well as more preoccupied with their symptoms and prone to 
developing depression (49). In summary, avoidance behavior contributes to a sustained fear of 
AF-related symptoms as well as disability, impairment and decreased QoL.  
A clinical model of the proposed role of symptom preoccupation in AF is illustrated in Figure 
2. Notably, the empirical data that underlie Figure 2 have only been collected in cross-sectional 
studies. Therefore, no firm causal conclusions about the directionality of the associations 





Figure 2. The role of symptom preoccupation in AF. 
 
2.3 CLINICAL STRATEGIES IN ATRIAL FIBRILLATION  
2.3.1 Pharmacological and invasive therapy 
As AF is a chronic disease and few interventions have been shown to sufficiently eliminate 
AF, the treatment of AF focuses on preventing thromboembolic complications, controlling 
symptoms and improving or preserving patients’ QoL. 
Most importantly, patients with AF have an increased risk of stroke or other thromboembolic 
events. Therefore, treatment guidelines for AF (50) recommend prophylactic oral 
anticoagulation to reduce the risk for stroke in those with additional risk factors (51). 
Furthermore, heart rate-controlling medications, such as betablockers, and rhythm-control 
strategies, such as cardioversion, antiarrhythmic drugs and catheter ablation to maintain and 
restore normal cardiac rhythm, are used to improve symptoms (50).  
Catheter ablation of AF is a well-established invasive treatment to prevent recurrent AF and 
reduce AF-related symptoms. In general, it is used as second-line treatment after 
antiarrhythmic medication intolerance, for example. The outcome of the procedure has been 
difficult to predict in individual patients, and it is also common that patients need more than 
one procedure to alleviate symptoms (52). Catheter ablation has been shown to be more 
effective than medical therapy in re-establishing sinus rhythm, but its long-term effect on 
QoL has been more uncertain (52). Recent studies show promising effects of catheter ablation 
on QoL, where the procedure on patients with AF compared to antiarrhythmic medication 
led to greater and sustained improvements in QoL 12 months after treatment (53,54). 
Prophylactic anticoagulation has shown to reduce mortality in AF patients by reducing risk 
for stroke, but interventions for rhythm control have less clear long-term mortality benefits 
 
 9 
(55). Emerging evidence indicates that in newly diagnosed symptomatic AF patients, early 
rhythm control interventions, such antiarrhythmic drugs and catheter ablation, are associated 
with lower risk for cardiovascular complication (56). Based on these findings, catheter 
ablation is the treatment of choice in patients with drug refractory symptomatic paroxysmal 
or persistent AF or based on patient preference.  
Despite improvements in the management of AF, current treatment strategies (pharmacological 
and invasive therapies) do not adequately alleviate symptoms in many patients with AF, and 
may also be associated with potentially serious side effects (57,58). With few easily accessible 
and effective treatment options available, AF places substantial demands on the healthcare 
system and there is a clear need for additional strategies to manage AF symptoms.  
2.3.2 Non-medical strategies to promote well-being  
Health care providers are recommended to educate their patients on the nature of AF, available 
treatment options and self-care activities, such as being physically active to prevent the 
progress of cardiovascular disease and to enhance well-being (59). Patient education that is 
commonly offered in routine care for AF has been associated with improved outcomes (60), 
and patients that are well-informed of their AF report more acceptance of their diagnosis, fewer 
symptoms and negative emotions related to their condition (61). This suggests that promoting 
patient education, understanding of AF and strategies to handle the symptoms could have a 
positive impact on both QoL and perceived symptom burden. Another factor that has been 
linked to increased well-being for AF patients is moderate physical activity, which is associated 
with reduced AF symptoms and increased QoL (62). Medical yoga has also been shown to 
improve QoL and  decrease blood pressure in patients with paroxysmal AF and has been 
suggested to be used as a self-management strategy (63). 
2.4 PSYCHOLOGICAL TREATMENT  
2.4.1 Cognitive behavior therapy  
Cognitive behavior therapy (CBT) is an established psychological treatment for both 
psychiatric and somatic conditions (64). Despite recognizing AF as a life-complicating disease 
associated with both anxiety and depression (35), CBT interventions are understudied in AF. 
Only two studies have evaluated psychological interventions specifically for AF: one pilot 
study using a brief intervention of mindfulness interoceptive exposure for AF patients (n=8) 
showed promising results in decreasing anxiety sensitivity (65); and a couples mindfulness-
based CBT-program for AF patients and their spouses showing effects on QoL (66).  
The effectiveness of CBT has been investigated in other cardiac conditions. According to a 
meta-analytical report on face-to-face CBT, cardiac disease treatments commonly consist of a 
variety of interventions targeting comorbid psychological conditions, such as anxiety and 
depression, with promising results (67). Stress management interventions, such as relaxation 
training, have been commonly used for cardiac conditions and have shown beneficial effects 
on mental and cardiac-related health, although with inconsistent effects across trials (68). 
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2.4.2 Exposure-based CBT 
Exposure-based CBT aims to reduce avoidance behavior, fear of symptoms and associated 
disability by applying systematic exposure to the stimulus and situations that evoke a fear 
response (69). Exposure-based CBT is the most empirically supported treatment in treating 
anxiety disorders, and exposure as a key component in CBT takes interoceptive (internal cues), 
imaginal or in vivo (external situations) forms (70). Exposure-based CBT, targeting disease-
specific anxiety and avoidance behavior using both interoceptive and exposure in vivo 
techniques accompanied with self-observation exercises, has shown to be effective in somatic 
functional disorders with regards to physical symptoms and QoL (71,72,73). In exposure 
therapy, patients are encouraged to broaden their behavioral repertoire in the presence of the 
feared symptoms or situation (74); e.g., participating in a work event while experiencing 
cardiac-related symptoms. Furthermore, a strategy to enhance exposure therapy is to use self-
observation during exposure (e.g., affect labeling), which has been shown to improve 
physiological reduction of fear (75). Despite the effectiveness of exposure-based CBT, several 
barriers for clinicians to deliver exposure based therapy have been identified, such as not 
wanting to cause distress in patients and applying it to patients with physical comorbidities 
(76). This suggests that exposure as a clinical treatment strategy might be underused in cardiac 
patients. Exposure-based CBT has been proven to be a safe option for patients with 
cardiovascular disease (77), but more clinical trials and interdisciplinary efforts are needed to 
evaluate the effectiveness of exposure-based therapy applied to cardiac patients. This thesis 
may contribute to bridging that gap of knowledge by studying exposure-based treatment in a 
scalable mode of delivery for AF patients.  
2.4.3 Internet-delivered CBT 
There is a substantial gap between the need for and availability of CBT (78), and by delivering 
the treatment via the Internet this gap can be somewhat bridged. There are several advantages 
to internet-delivered CBT, one of them being increased accessibility. The treatment can be 
made available to patients in rural areas, and patients can access the treatment at flexible hours. 
Internet-delivered CBT also allows for centralizing the expertise necessary for delivering safe 
treatments. The mode of delivery enables treatment of a larger number of patients because less 
therapist time is required per patient (79). Furthermore, since the treatment content is structured 
it also reduces the effects of therapist drift and non-specific treatment factors (80) and, in 
general, treatment effects of internet-delivered CBT are similar to those of face-to-face CBT 
(81).  
Internet-delivered CBT has shown effective for a range of somatic and psychiatric disorders 
(79), but few studies have investigated internet-delivered CBT for cardiac diseases (67) and 
there has been a demand for increased access to digital interventions within cardiac healthcare 
(82). Although evidence that internet-delivered CBT for anxiety and depression in cardiac 
diseases is scarce, two recent randomized controlled trials showed promising results in several 
outcomes indicating that internet-delivered CBT is both effective and acceptable to cardiac 
patients (83,84). Internet-delivered CBT has also been evaluated for non-cardiac chest pain, 
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where patients show fear of bodily symptoms and cardiac disease leading to avoidance 
behavior, demonstrating comparable results in the reduction in cardiac anxiety and perceived 
chest pain as in traditional face-to face CBT (85,86).  
2.5 SUMMARY OF THE BACKGROUND  
AF is a prevalent arrhythmia associated with both somatic and psychological impairments. 
Symptom preoccupation – i.e., cardiac-related fear and avoidance behavior – may play a role 
in AF disability. Current treatment strategies do not sufficiently alleviate symptoms in many 
AF patients, thus developing a multidisciplinary approach to managing AF is warranted. CBT 
has shown promising effects in other somatic and cardiac disorders but is understudied in AF. 
In order to improve QoL and psychological and physical functioning in AF patients, we need 
to further understand mechanisms that drive AF disability and develop effective and scalable 





3 RESEARCH AIMS 
The overall objective of my doctoral project was to develop and evaluate a novel, AF-specific 
exposure-based, internet-delivered CBT protocol to potentially reduce symptom burden and 
increase QoL in patients with paroxysmal AF. The studies of the doctoral project were 
conducted in a sequential order; i.e., firstly, a face-to-face pilot study of CBT for AF (AF-
CBT), then a pilot study of the treatment protocol delivered via internet and finally evaluating 
the protocol in a randomized controlled trial (RCT). Each study was designed to gain clinical 
and procedural experiences and apply these experiences to the following study. In addition to 
the clinical trials, a mediation analysis on the collected data from the RCT was conducted to 
further explore psychological mechanisms of change in CBT for AF. The aims of the studies 
are described below.  
3.1 STUDY I 
The aims of Study I were to develop an exposure-based, AF-specific CBT protocol for patients 
with paroxysmal AF and to assess if the treatment was feasible, acceptable and potentially 
efficacious.   
3.2 STUDY II 
The aims of Study II were to evaluate the efficacy, feasibility and safety of internet-delivered 
AF-CBT in preparation for a forthcoming RCT. The hypothesis was that the treatment would 
be feasible and potentially effective based on the results in Study I. Additional aims of the study 
were to investigate changes in objectively measured AF burden as well as to explore potential 
mediators of treatment effect on AF-specific QoL.  
3.3 STUDY III  
The aims of the Study III were to evaluate the effectiveness of exposure-based, internet-
delivered AF-CBT compared with a waitlist control group that was offered standardized AF 
education in an RCT, and to explore changes in objective AF burden. Our hypothesis was 
that AF-CBT would lead to superior improvements than the control group. 
3.4 STUDY IV 
Study IV was based on data from the RCT and its aim was to investigate psychological 
mediators (i.e., cardiac-related fear, hypervigilance, avoidance and stress) of the treatment 
outcome. We hypothesized that improvements in AF symptoms and AF disability would be 




4 EMPIRICAL STUDIES  
4.1 STUDY I: EXPOSURE-BASED THERAPY FOR SYMPTOM 
PREOCCUPATION IN ATRIAL FIBRILLATION: AN UNCONTROLLED 
PILOT STUDY 
Aim 
The aims of the study were to develop an exposure-based AF-specific CBT protocol for 
patients with paroxysmal AF and to assess if the treatment was feasible, acceptable and 
potentially efficacious.   
Methods 
The study was an uncotrolled pilot study that included 19 patients diagnosed with symptomatic 
paroxysmal AF. The CBT treatment lasted for 10 weeks and was delivered in a traditional face-
to-face format at the Karolinska University Hospital. The intervention was tailored to AF over 
the course of the treatments based on clinical presentation. The study design included 
assessments at pre-treatment, post-treatment and six-month follow-up. Piecewise-linear mixed 
models were used to estimate within-group effects from baseline to post-treatment and from 
post-treatment to six-month follow-up. Effect sizes were calculated using Cohen’s d (71) where 
small, medium and large effect sizes are proposed to correspond to d = 0.20, 0.50, and 0.80, 
respectively. The primary outcome  was The Atrial Fibrillation Effect on QoL (AFEQT), which 
measures self-reported AF symptoms and AF-specific QoL (87). Secondary outcome measures 
included self-reported frequency and severity of AF symptoms, general anxiety, depression, 
stress and health-related QoL. Adherence (e.g., session attendance and engagement with 
exposure exercises) and satisfaction with the treatment were used as measurements of 
feasibility and acceptability.  
Main Results 
We observed large treatment effects in self-reported AF-specific QoL and AF symptoms 
(Cohen’s d=1.54; p<. 001) post-treatment, as measured by the primary outcome AFEQT. 
Improvements were sustained at six-month follow-up. Furthermore, we observed large pre- to 
post-treatment effects in self-reported severity and frequency of AF symptoms. At post-
treatment, we observed moderate to large significant improvements the rest of the outcome 
measures. At six-month follow-up, we although observed a decline in treatment effects. The 




4.2 STUDY II: INTERNET-DELIVERED EXPOSURE-BASED THERAPY FOR 
SYMPTOM PREOCCUPATION IN ATRIAL FIBRILLATION: 
UNCONTROLLED PILOT TRIAL 
Aim 
The aims Study II were to evaluate the efficacy, feasibility and safety of internet-delivered AF-
CBT. Additional aims of the study were to investigate potential changes in objectively 
measured AF burden as well as to explore potential mediators of treatment effect on AF-
specific QoL.  
Methods 
In an uncontrolled pilot study, 19 patients diagnosed with symptomatic paroxysmal AF 
underwent internet-delivered CBT for 10 weeks. The treatment was therapist guided and 
included exposure to physical sensations, exposure to avoided situations and behavioral 
activation. During the study, participants completed weekly self-assessments and handheld 
ECG measurements with symptom registration at pre-treatment, post-treatment and at six-
month follow-up. Piecewise-linear mixed models were used to estimate the means and Cohen’s 
d to calculate effect sizes. The primary outcome was AFEQT and secondary outcomes included 
self-reported frequency and severity of AF symptoms, health care visits, cardiac anxiety, 
depression, stress and general QoL. Feasibility was assessed with regards to treatment 
satisfaction, number of completed modules and data collection on adverse events.  
Main results 
Large within-group improvements were observed in AF-specific QoL (Cohen’s d=0.80; P<. 
001), and in symptom preoccupation (Cohen’s d=1.24; P<. 001). The results were sustained 
six months after the treatment had concluded. Eighty-four percent of the participants were 
considered treatment completers. Treatment adherence as well as satisfaction with treatment 
were high. There were also very few and transient adverse events. At six-month follow-up we 
saw an increased AF burden, as measured by ECG. Interestingly, we observed a significant 
decrease in participants’ overestimation of AF symptoms post-treatment and at six-month 
follow-up. Exploratory within-group mediation analysis indicated that reduction in symptom 




4.3 STUDY III: INTERNET-DELIVERED COGNITIVE BEHAVIORAL THERAPY 
FOR SYMPTOM PREOCCUPATION IN ATRIAL FIBRILLATION: A 
RANDOMIZED CONTROLLED TRIAL  
Aim 
The aims of Study III were to evaluate the effectiveness of exposure-based internet-delivered 
AF-CBT compared with a waitlist offered AF education and to explore changes in objective 
AF burden. 
Methods  
We included 127 patients diagnosed with paroxysmal symptomatic AF who were randomized 
to 10 weeks of AF-CBT (n=65) or to an AF education waitlist (AF-EDU; n=62). Participants 
completed self-assessments pre-treatment, weekly during treatment, post-treatment and at 
three-month follow-up, along with continuous ECG measurements (e-patch) over five days to 
evaluate AF burden at the main assessment points. The primary end point was AF-specific QoL 
measured by AFEQT three months post-treatment, after which patients in the AF-EDU group 
were crossed over to AF-CBT. Secondary outcomes included self-reported frequency and 
severity of AF symptoms, AF health care visits, cardiac anxiety, depression and general QoL. 
The AF-CBT group was also evaluated six and 12 months after treatment. The outcome 
analyses were based on an intention-to-treat, and we used hierarchical linear mixed-effect 
modeling to estimate if there was a significant interaction effect between group and time. Effect 
sizes were calculated using Cohen’s d.  
Main Results 
AF-CBT led to a large and significant improvement in AF-specific QoL. The mean QoL score 
using AFEQT was 62.4 at baseline and increased by 21.0 points in the AF-CBT group 
compared with 6.0 points in the AF-EDU group (95% CI in difference: 10.1-19.8; P<.001) 
(Figure 3). AF-CBT also showed significant improvements in all the secondary outcomes 
compared with the control group; e.g., AF symptoms frequency and severity (P<.001), 
symptom preoccupation (P<.001), general QoL (P<.001), and AF-specific health-care 
(P<.0.027). The results were sustained 12 months after treatment. With regards to objective AF 
burden as measured by ECG, we observed no significant difference between the groups at the 
primary endpoint. Figure 3 displays the change in AFEQT score over the study period. 
 
Figure 3. Change in AFEQT score over study period. 
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4.4 STUDY IV: THE ROLE OF CARDIAC-RELATED FEAR, HYPERVIGILANCE 
AND AVOIDANCE BEHAVIOR IN EXPOSURE THERAPY FOR ATRIAL 
FIBRILLATION: A MEDIATION ANALYSIS  
Aim 
Study IV was based on data from the RCT in Study III, and its aim was to investigate 
psychological mediators (i.e., cardiac-related fear, hypervigilance, avoidance and stress) of the 
treatment outcome. 
Methods 
The study was based on data from the RCT (Study III; N=127) that evaluated AF-CBT 
compared with a waitlist offering AF education. The main outcome variables (AF symptoms 
and AF disability) and the putative mediators (cardiac-related fear/hypervigilance, avoidance 
and stress) were measured weekly throughout the treatment. 
Parallel process growth models were used to estimate the effect of the treatment and putative 
mediators on the outcome. We also used a random cross-lagged panel model to assess the 
direction of change; i.e., if week-by-week change in the putative mediator preceded the within-
individual week-by-week change in the outcome.  
Main results  
Results from parallel process growth models indicated that improvements in cardiac-related 
fear/hypervigilance and avoidance behavior, but not perceived stress, mediated the controlled 
effect of AF-CBT on both AF symptoms and AF disability. However, in random-intercepts 
cross-lagged panel models of the within-individual week-by-week interrelationships of 
potential mediators and outcomes, cardiac-related fear/hypervigilance was the only mediator 
in which changes were systematically predictive of subsequent changes in AF symptoms. 
Furthermore, avoidance behavior was the only mediator in which changes were systematically 





The participants in Study I and II were referred by cardiologists in the greater Stockholm area 
and then further assessed by the study team consisting of a cardiologist and clinical 
psychologist before entering the study. Participants in Study III were recruited nationwide by 
patient self-referral in response to advertisements in daily press and on social media. After an 
online eligibility screening, participants underwent a cardiac assessment by a cardiology nurse 
and a cardiologist at Karolinska University Hospital as well as a psychological assessment by 
a clinical psychologist. Eligible criteria for Studies I-III are presented in the table below.  
The mean age of the participants across the studies ranged from 60.5 to 65.4 years. In Study I, 
63% of the sample consisted of men, whereas in Study II and III, 63% and 58%, respectively, 
consisted of women. Most participants had a university degree, 37–53% were currently 
employed and 37–59% were retired. The mean duration of AF since the first diagnosis was 
between 5.6 and 8.3 years and 10–42 % had undergone a previous treatment attempt with 
catheter ablation. Participants who had previously undergone psychological treatment in some 
form ranged from 28 to 63%. The baseline mean AFEQT score (AF-specific QOL) ranged 
from 56.9 to 66.8, corresponding to moderate AF severity.  
 
Table 1. Inclusion and exclusion criteria for Studies I-III. 
Inclusion criteria Exclusion criteria 
(A) paroxysmal AF with an average of ≥1 AF 
episode(s) per month. 
E) heart failure with a left ventricular ejection 
fraction ≤35% or significant valvular 
disease. 
(B) optimal medical care according to 
current clinical guidelines . 
F) planned ablation for AF or ablation within 
three months before assessment. 
(C) symptoms experienced as troubling or 
causing limitations in daily activities (i.e., 
European Heart Rhythm Association 
(EHRA) class ≥ IIb (88). 
G) other severe medical illness or any 
medical restriction to physical exercise. 
(D) aged 18-75 years. H) other severe psychiatric disorder, risk of 
suicide, alcohol dependency or concurrent 





4.6 THE TREATMENT: EXPOSURE-BASED AF-CBT 
In the treatment, we used an exposure-based approach specifically targeting symptom 
preoccupation and hypothesized to play a role in AF-related disability. The intervention used 
in the Studies (I-III) aimed to reduce fear and hypervigilance of AF symptoms and AF-related 
avoidance behavior.  
The following components were included in the treatment: i) education on AF 
(pathophysiology and medical treatment) and the negative cycle of cardiac-related fear, 
hypervigilance and avoidance behavior; i.e., symptom preoccupation; (ii) self-observation 
exercises (i.e., observing cardiac-related symptoms, thoughts, emotional responses and 
behavioral responses) as planned exercises and when experiencing symptoms. The labeling of 
internal cardiac-related stimuli aimed to increase tolerance of bodily symptoms; it also guided 
participants to willingly focus on thoses symptoms, thus enhancing the effect of exposure; (iii) 
exposure to cardiac-related physical sensations by conducting interoceptive exposure exercises 
such as inducing palpitations by running on the spot, focusing on the heart while lying on the 
left side or inducing dyspnea by over-breathing. Participants were instructed to repeat the 
exercises until symptom fear was significantly reduced; (iv) in-vivo exposure to avoided 
activities and situations in which symptoms are anticipated or while experiencing symptoms. 
The varied forms of exposure were often used together, and we also encouraged participants to 
apply the self-observation exercise while conducting exposure or while experiencing AF 
symptoms; (vi) reduction or removal of excessive symptom controlling behaviors, such as 
gradually reducing pulse checking; (vii) behavioral activation, where patients worked towards 
increasing valued behaviors within life areas impaired by AF; (viii) relapse prevention and how 
to maintain an active lifestyle if or when experiencing an increase in AF symptoms. .  
4.7 MODE OF DELIVERY AND ADAPTATIONS OF THE TREATMENT 
The CBT treatment in Study I was made up of 10 weekly face-to-face sessions with homework 
assignments at the department of cardiology, Karolinska University Hospital. The intervention 
was derived from an exposure-based CBT protocol for IBS targeting gastrointestinal-specific 
anxiety and avoidance behavior (71,72) and tailored to AF based on the participants’ responses 
to the treatment and clinical presentation. The internet-delivered treatment in Study II and III 
consisted of six interactive treatment modules with homework assignments. After the fifth 
module, participants worked with the exercises continuously and reported weekly to their 
assigned therapist. In the last week of the treatment, participants worked with a relapse 
prevention module. Therapist support was provided via written feedback on the assignments 
within the online treatment platform. The therapist could consult the study cardiologists with 
regards to specific questions about how to conduct an exposure exercise in a safe manner or 
questions on the participants’ physical health.  
For Study II, the treatment was adapted to an internet format and then further revised and 
streamlined for Study III. Most of the participants had successfully conducted therapist-lead 
exposure exercises, such as running stairs and increasing their heart rate, at the site. In Study 
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II, the protocol was designed to maximize the likelihood that the participants would conduct 
exposure exercises on their own with an extensive rationale on how to conduct exposure 
exercises, clinical vignettes and case examples, as well as information on safety parameters and 
directions on how to engage partners in the treatment. For example, we provided a rationale to 
the participants on how AF symptoms could be viewed as an occasion to apply new skills 
gained via the treatment. As a safety precaution and as a way to help participants differentiate 
between cardiorespiratory symptoms and symptoms that require medical attention, all 
participants were informed that if they experienced sensations of fainting, syncope or exercise-
induced chest pain ,they should cease the exposure exercise and consult their treating physician. 
Because we had observed an overall trend of decline in treatment effect in Study I at follow-
up, we further developed the module on relapse prevention in the final step and included 
strategies to address potential progression of AF.   
For the treatment protocol in Study III, we further adapted the protocol and made it even more 
streamlined towards exposure exercises. We commenced with exposure exercises earlier on in 
the treatment (session 3), we also used fewer but more cardiac-specific interoceptive exposure 
exercises, such as lying on the left side and observing the heart for three minutes, to enhance 
exposure and tolerance of the phobic stimulus; i.e., the heart. Furthermore, we expanded the 
rationale of exposure to include a range of negative affects (e.g., irritability, discomfort) in 
response to AF and also included examples of habitual avoidance to be able to capture a broader 
range in the clinical spectra. We also created a list of AF-related controls and avoidance 
behaviors, where participants mapped their behaviors out in session 2 (see Figure 4). The list 
was used throughout the treatment and later used to track and monitor the progress of the 
exercises. The list also provided an overview for the therapist to encourage the participants to 
conduct repeated exposure exercises across a broad range of behaviors, impressing upon the 






Figure 4. Screenshot of AF-behaviors used to monitor exposure exercises. 
 
4.8 SAFETY PARAMETERS AND ETHICAL CONSIDERATIONS  
AF is associated with both cardiovascular conditions as well as a variety of psychological 
comorbidities, and when conducting these interdisciplinary treatment studies several ethical 
considerations in this doctoral project have been taken into account.  
The study team thoroughly worked through the eligibility criteria for the patients participating 
in the treatment to maximize patient safety. The inclusion criteria for patients consisted of some 
of the following: that the patients received AF care according to current guidelines; that they 
did not suffer from severe cardiovascular disease (heart failure with severe systolic dysfunction 
(ejection fraction ≤ 35%)); that they did not have significant valvular disease or other severe 
medical illnesses that may restrict the patients’ ability to be physically active; or that they had 
a severe psychiatric condition or alcohol dependency. To ensure these eligibility criteria were 
met, the inclusion procedure comprised both a cardiac and psychological assessment. All 
patients in the studies underwent a cardiac assessment by the study cardiologist (Studies I and 
III) or by the referring cardiologist (Study II), as well as a structured psychological assessment 
by a clinical psychologist. The cardiac assessments included an echocardiogram, ECG and 
blood pressure measurement. Documentation of the AF diagnosis was also reviewed and 
approved by a cardiologist belonging to the research team before a decision on inclusion was 
made. The treating psychologists received training in AF by the study cardiologist and were 
able to consult the study cardiologists at any given point during the treatment. 
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Engaging in the CBT treatment includes physical activity which may lead to an increased heart 
rate and give symptoms reminiscent of AF episodes. Importantly, physical activity is 
recommended in treatment guidelines and is not considered to imply any risk for AF patients 
included in the study. Although as a safety precaution, we instructed participants to stop the 
exposure exercises if they experienced exercise-induced chest pain, syncope or a sensation of 
fainting and contact a physician before proceeding. They were also informed that they should 
follow their treatment as usual and that their treating physician had continued responsibility for 
their medical treatment. The study design, with weekly assessments and the continuous contact 
with the patient, provided the clinical psychologist with good control over progress in 
treatment. Furthermore, daily online contact in the internet-delivered format provided the 
participants and psychologist the opportunity to communicate on a regular basis and therefore 
identify any negative changes in physical or mental health. 
The research group carefully selected well-known and validated assessment tools to reduce the 
burden of filling measurements. All self-rated measures were completed online and the data 
was securely stored in accordance with applicable laws and regulations. Finally, all the studies 
included in this doctoral project were registered in the ClinicalTrials.gov trial registry, and all 
studies will be reported in accordance with the CONSORT statement for non-pharmacological 
trials and approved by the Regional Ethical Board, Stockholm, Sweden. Overall, the ethical 
aspects of the studies were thoroughly assessed by the research group, keeping the participants’ 





Within the scope of this thesis, a novel exposure-based and internet-delivered CBT protocol 
was developed to improve QoL in patients with symptomatic paroxysmal AF. Based on the 
experience from two pilot studies showing the feasibility and efficacy of AF-CBT in a face-to-
face and internet-delivered format, an RCT was conducted demonstrating significant 
improvements in AF-specific QoL, self-reported AF symptoms and symptom preoccupation in 
addition to a broad range of secondary outcomes. The participants demonstrated high 
adherence and treatment satisfaction. Furthermore, the reduction of symptom preoccupation 
mediated the treatment effect of self-reported AF symptoms and disability. The findings are 
further discussed below.  
5.1 IS EXPOSURE-BASED AF-CBT ACCEPTABLE, FEASIBLE AND SAFE 
FOR PATIENTS WITH AF? 
When we started this project, CBT had never been evaluated in the treatment of AF. At the 
start of Study I, we were uncertain how patients would respond to CBT for their arrhythmia, a 
condition with a well-established pathophysiology, commonly not considered for 
psychological treatment. Previous research had shown that exposure-based CBT had been 
efficacious and acceptable for patients with other somatic disorders, and since anxiety and 
psychological distress were prevalent in AF, it made clinical sense to explore the effect of 
exposure-based CBT for AF patients.  
We conducted two pilot studies to build clinical and procedural knowledge on how to best treat 
AF with CBT. In Study I, the treatment protocol was developed based on clinical presentation, 
and its acceptability and preliminary efficacy was investigated. In Study II, the treatment 
protocol was further revised and adapted to an Internet format. Finally, in Study III the 
treatment was further tailored for the AF population and was evaluated with regards to its 
efficacy and acceptability in an RCT.  
At post-treatment across the trials, we observed high scores in treatment satisfaction as 
measured with the Client Satisfaction Questionnaire (CSQ-8; range 8-32 with a higher score 
indicating greater satisfaction): from Study I, 32 points; Study II, 25 points; and Study III, 26 
points corresponding to “very satisfied” with the treatment, with a slightly higher score in the 
face-to-face-treatment. Furthermore, the large majority of participants rated that the treatment 
helped them to manage their AF symptoms more effectively. Across the trials (Study I-III), we 
found adherence to the treatment to be high, with 83-100% of the participants completing the 
treatment, indicating that the treatment was acceptable. The reported adherence to the treatment 
is considerably higher than the 58% adherence that has been reported in adult meta-analysis of 
internet-delivered CBT (89). The high treatment satisfaction and adherence are important 
indicators that exposure-based CBT is a feasible and acceptable treatment for AF patients.   
No adverse cardiac events were reported during the course of the treatments or when patients 
were conducting exposure exercises. There were very few reported general adverse events from 
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participating in Study I-III; e.g., 4 out of 65 patients in the AF-CBT group in the RCT reported 
increased cardiac attention or stress due to the study procedure with mild and transient adverse 
effects. This suggest that the use of exposure-based interventions, both interoceptive and in-
vivo, are both safe and acceptable for the target group.  
The two pilot studies provided evidence for the feasibility, acceptability and safety of the 
exposure-based treatment protocol which was later confirmed in the RCT. In summary, the 
patients’ high adherence to and satisfaction with the treatment along with the positive results 
obtained in multiple domains of AF disability and limited reports of adverse events, indicate 
that exposure-based AF-CBT is a safe and acceptable treatment option for AF patients.  
5.2 IS AF-CBT EFFECTIVE FOR PATIENTS WITH AF? 
Exposure-based AF-CBT was shown to be effective (Study I-III) when delivered face-to-face 
and via the Internet. When investigating the efficacy of AF-CBT compared with a waitlist 
offered standardized AF education, we observed superior improvements for the treatment 
group on the primary outcome, AF-specific QoL measured by AFEQT and across the 
secondary outcomes of symptom preoccupation, self-reported frequency and severity of AF 
symptoms, general QoL, depression, and health care consumption. The treatment effect was 
maintained 12 months after the treatment. The mean summary AFEQT score corresponded to 
moderate AF severity at baseline, and at post-treatment and 12-month follow-up it 
corresponded to mild AF severity. The effects obtained on the primary outcome are comparable 
to changes achieved in AF-specific QoL in recent rhythm control (medical therapy) and 
ablations trials (54). Furthermore, the effect sizes obtained are also in line with effects of 
internet-delivered exposure-based CBT for other somatic conditions, including cardiac disease 
(90,83,84).  
The internet-delivered treatment may be considered a cost-effective alternative, with therapist 
time ranging from a weekly mean of 5.7–9.5 minutes per patient in Study II and III (compared 
with approximately one hour per week in face-to-face CBT). The internet-delivered format 
provides high accessibility for patients, and the low therapist time expended offers an 
opportunity to treat a large number of patients. The treating psychologists can be located 
virtually anywhere, and internet-delivered AF-CBT also allows for centralizing the expertise 
necessary for delivering safe treatments in collaboration with cardiologists. 
Throughout the clinical trials, we observed medium to small effects on depression, which may 
be explained by average baseline scores below clinical ranges (91). This leaves little room for 
improvement and thus smaller effect sizes. Depression and perceived stress may be secondary 
to symptom preoccupation in AF, further emphasizing the importance of targeting disease-
specific mechanisms of disability in AF. Paroxysmal AF has been associated with high 
healthcare utilization and costs (21). Helping patients develop strategies to handle their 
symptoms rather than repeatedly consulting the healthcare system may help reduce these costs. 
AF-CBT showed the potential to reduce healthcare consumption; more specifically, we 
observed that AF-CBT led to a significant reduction of cardiac-specific health care seeking in 
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Study III, where patients consumed 56% less AF-specific health care compared with the control 
group.  
We observed an increase in the objectively measured AF burden (Study II). In Study III, no 
difference in AF burden was observed between the groups at three-month follow-up and, over 
the whole sample, there was a tendency towards an increased AF burden. These results indicate 
that AF-CBT does not affect the underlying disease, but despite a tendency of increased AF 
burden, which is expected since the natural course of AF is associated with a gradual increase 
of AF burden over time (11), participants were still able to achieve large improvements in QoL 
and symptom preoccupation. Furthermore, we observed low rates of reported deterioration in 
cardiac health in the studies at six-month follow-up (Study I and II) and at 12 months after the 
treatment had concluded (Study III). In Study III, the reported deterioration in cardiac health 
in AF-CBT was low and compared favorably with the control group at 12% and 24%, 
respectively, and there were few changes in medication and cardiac-related procedures. A 
possible future direction of research could be to investigate if AF-CBT can have an impact on 
the preservation of cardiac health and lower the risk for cardiovascular complications.  
In summary, internet-delivered exposure-based AF-CBT is effective in improving AF-specific 
QoL for patients with symptomatic paroxysmal AF already receiving routine care at baseline. 
We also observed promising results on several outcomes that were sustained 12 months after 
the treatment.  
5.3 DOES REDUCTION IN SYMPTOM PREOCCUPATION MEDIATE CHANGE 
IN TREATMENT OUTCOME? 
Study III was the first RCT of exposure-based AF-CBT targeting symptom preoccupation in 
AF. Based on the promising effects in that study, we wanted to further explore the processes 
of change in subjectively rated AF symptoms and disability in Study IV. We also hoped to 
further understand the psychological factors driving AF-disability beyond the physical disease. 
We investigated cardiac-related fear/hypervigilance and avoidance, and perceived stress as 
potential mediators. We observed that reduction in cardiac-related fear/hypervigilance, but not 
perceived stress, mediated the effect of AF-CBT on AF symptoms and disability. Furthermore, 
reduction in cardiac-related fear/hypervigilance predicted changes in AF symptoms, whereas 
reduction in avoidance behavior seemed to be a key mechanism in reducing AF disability.  
The results of this study are in line with previous mediation studies of CBT in cardiac disease 
and noncardiac chest conditions, where reduction in somatic or cardiac anxiety predicted 
subsequent reduction in cardiovascular outcome and somatic symptoms (92,85). The results 
are also in line with other mediation analyses of exposure-based CBT, where the reduction in 
disease-specific anxiety and avoidance behavior was found to mediate the effect on other 
functional health conditions (89,93,94).  
The results from the mediation analysis have clinical and scientific relevance by demonstrating 
how psychological factors may contribute to symptom severity and disability in AF. The 
studies also support the treatment model where systematic exposure, both interoceptive and in-
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vivo, targeting cardiac-related fear, hypervigilance and avoidance, lead to reduced symptoms 
and increased functioning in AF. Incorporating the knowledge of the role cardiac-related fear 
and avoidance behavior play in AF management could lead to the development of more tailored 
clinical strategies.  
5.4 VALIDITY AND GENERALIZABILITY OF THE RESULTS  
When interpreting the results of this doctoral project some limitations must be considered. In 
Study I and II there were no control groups, which limit the causal conclusion on efficacy. The 
use of a waitlist control in Study III does not control for unspecific treatment effects, such as 
attention from caregiver. Nevertheless, since the waitlist was offered standardized AF-
education, filled in weekly measurements as well as ECG-measurements and knew that they 
would receive AF-CBT, these factors may have acted as an attention control to some extent.  
In Study I and II, recruitment was slow as participants were referred from tertiary care. The 
slow referral was potentially due to a high workload for clinicians or maybe due to problems 
identifying which patients would be suitable for CBT. This led us to use self-referral as 
recruitment method in the RCT, which allowed us in this first evaluation of the efficacy of AF-
CBT, to conduct a well-powered study with participants from all over Sweden. There are 
therefore some points that are interesting to highlight with regards to the generalizability of the 
results: for example, more than half of the participants in Study I and II had attended some sort 
of previous psychological counseling. It is therefore a possibility that these patients were more 
open to psychological treatment than the general AF patient. However, in Study III, which used 
self-referral, only 28% of the patients had previous experience of psychological treatment. The 
use of self-referral may have led to a sample that was more similar to AF patients seen in regular 
healthcare.   
With regards to AF severity, we observed that the mean score in AF-specific QoL of the 
samples in Study I-III corresponded to moderate AF severity, indicating that the participants 
were representative to average AF patients. In general, the sample also consisted of more 
women and were younger than the average AF population, which may limit the generalizability 
of the results on one hand; but on the other hand, since being of female sex and of younger age 
have been associated with more impaired QoL in AF (24), it is not unexpected that there were 
proportionally more women in the study samples. 
Furthermore, the number of patients in the clinical diagnostic interview in Study III that were 
assessed with depressed mood (29%) or any anxiety disorders (24%) or any psychiatric 
comorbidity (in Studies I and II (21-26%)) are comparable with findings investigating elevated 
levels of anxiety and depression in AF (31). This reflects that the proportion presenting with 
anxiety and depression in the study is comparable to the average AF population. We also found 
that 65% of the participants in Study III fulfilled the diagnostic criteria of Somatic Symptom 
Disorder (SSD), which is a diagnosis characterized by impairments following emotional and 
behavioral responses to somatic symptoms. The number of participants showing symptom-
specific anxiety further strengthens our disease-specific model targeting symptom 
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preoccupation. When assessing SSD in the general population it has been shown to be more 
prevalent in patients with underlying medical disorders (95). Whether the proportion of SSD 
observed in the study corresponds to the general AF population has yet to be investigated; there 
is no current data available on this matter. Also, assessing if the presence of SSD is a predictor 
for treatment response could also be of further interest. 
Finally, the results from the mediation analysis (Study IV) have to be interpreted with some 
limitations in mind: for example, the treatment did not target stress and that mediator was 
primarily included to control for specificity of the proposed mediators. Furthermore, there is 
no guarantee that the change in the outcome that is explained by the preceding change in the 
mediator corresponds to the variance explained by AF-CBT. Another limitation is that the 
CAQ subscale measuring avoidance mostly dealt with avoidance of physical activity, and 
investigating the broader range of avoidance behaviors that is targeted by AF-CBT would 
have been preferable to more fully investigate the active treatment mechanism.  
5.5 CLINICAL IMPLICATIONS 
The observed effects of AF-CBT were achieved in symptomatic patients already receiving 
medical therapy according to clinical guidelines, which also was reflected in the cardiac 
parameters of the sample characteristics. This suggests that AF-CBT is an effective treatment 
and can be used for AF patients presenting with symptom preoccupation despite optimal 
medical care. We also observed that around 10-40% of the participants in the clinical studies 
had undergone at least one ablation, indicating that CBT could be suitable option for patients 
who are still troubled by their symptoms despite invasive therapy. AF-CBT can also function 
as a treatment option for patients that are not eligible for invasive therapies or as an alternative 
option based on the patients’ preference of treatment.  
Our results demonstrate that psychological factors may contribute to symptom severity and 
disability. This knowledge should ideally also be integrated in AF management; in, for 
example, standardized AF education when patients are being diagnosed with AF as well as to 
identify symptom preoccupation in AF patients. Another way to integrate this in clinical 
practice could be to use the already well established EHRA scale classification class ≥IIb (88); 
i.e., symptoms that trouble the patient or cause limitations in daily life. We used the EHRA 
scale classification class ≥IIb (88) as an inclusion criterion across the clinical trials and suggest 
that patients fulfilling EHRA class IIb also might be presenting with patterns of symptom 
preoccupation. EHRA class IIb has shown to correlate with moderate AF severity (AFEQT 
(88)) as seen in our study samples, and could be used as clinical indication for healthcare 
professionals to further screen patients for psychological impairments or for referring to AF-
CBT. 
This novel interdisciplinary approach to AF demonstrates increased QoL and reduced health 
care utilization in a safe manner. In order to have a positive impact on patient wellbeing and 
routine clinical practice, we hope to make the treatment accessible for the target population on 
a large scale by implementing and disseminating AF-CBT within routine care. I think that AF-
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CBT for AF patients presenting with symptom preoccupation could be used as a treatment 
option in different steps of AF care: for patients newly diagnosed with AF; following, for 
example, invasive therapy; or as an addition to routine AF care. The manual-based structured 
format allows for a brief training period for psychologists who could then deliver AF-CBT via 
a national Internet treatment unit, in collaboration with a cardiologist assigned to oversee the 
medical safety parameters.  
5.6 FUTURE DIRECTIONS 
This doctoral project has shown promising effects in the first evaluation of internet-delivered 
exposure-based AF-CBT for AF patients with symptom preoccupation. We used a low-
intensity control condition in the early phase of evaluating this novel treatment to minimize the 
risk of committing Type II-errors. But in a coming trial, we will use an active control group to 
further evaluate the treatment protocol and isolate treatment-specific effects. We are planning 
to conduct an RCT in the fall of 2021, where AF-CBT will be compared with a stress 
management intervention. This will further help us understand treatment-specific mechanisms 
and to evaluate the long-term effects of AF-CBT compared with an active control group. 
In addition to the mediation analysis, it would be of interest to further explore the active 
mechanism of the treatment, and to which magnitude of change are the treatment components 
attributable (e.g., interoceptive exposure, exposure in-vivo or self-observation [i.e., affect 
labeling]) by using a dismantling design. In addition to this, it might be effective to conduct 
prediction analysis to further investigate for whom the treatment is effective, with regards to 
AF severity and psychological correlates, for example. This knowledge could further be used 
to evaluate AF-CBT in a brief and easily applied format consisting of, for example, one session 
of psychoeducation and interoceptive exposure in conjunction to receiving the AF diagnosis, 
to possibly minimize the development of symptom preoccupation.  
Extending the follow-up time could also provide us with information on if and when the 
treatment effects start to decline and whether, for example, a booster session could benefit 
patients. Furthermore, empirically based insight into psychological processes that shape long-
term outcomes could be explored using registry data. For example, it would be interesting to 
explore if AF-CBT has the potential to reduce other cardiovascular risk factors by collecting 
follow-up data from patient registries.  
Encouraged by the results of CBT in AF, we have adapted the exposure-based treatment to two 
other cardiac conditions where symptom preoccupation may affect the clinical course. We are 
currently investigating exposure-based CBT for premature ventricular contraction (extra 
heartbeats) and in patients following myocardial infarction. A long-term goal would be to build 
a similar research program and interdisciplinary knowledge base for a broad range of cardiac 






Internet-delivered AF-CBT is a feasible and effective treatment for AF patients that 
significantly improved AF-specific QoL, self-reported AF symptoms, symptom preoccupation 
and health care consumption in patients with symptomatic paroxysmal AF already receiving 
routine AF care. The effects were sustained 12 months after the treatment had concluded. 
Exposure-based AF-CBT delivered via the Internet has the has the capacity to ameliorate the 
well-being of a large group of patients who do not sufficiently improve from current treatment 
methods. Symptom preoccupation, i.e., cardiac-related fear, hypervigilance and avoidance, is 
an important target for treatment, mediates the reduction of symptoms and increases 
functioning in AF. The results in this thesis support the integration of psychological evaluation 
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